Kelly's Heroes: Fighting Pancreatic Cancer

08/26/2026

Today, the FDA formally authorized a first-if-its kind drug called daraxonrasib that's being described as a gamechanger in the fight against pancreatic cancer. Daraxonrasib is an RAS inhibitor - its superpower is blocking a group of proteins called RAS that fuel tumor growth. In clinical trials, patients given daraxonrasib survived twice as long as those who received the standard of care. And, daraxonrasib is a simple pill taken once a day, with much less debilitating side effects than chemotherapy. It is, quite simply, the brightest spark of hope against this disease in a very long time!

RASONQUE™ (daraxonrasib) is approved for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This is now considered the new standard of care for patients with previously treated metastatic pancreatic cancer after clinical trial results in this population showed a doubling of survival compared to chemotherapy as well as improved quality of life for patients.

Visit 🔗 https://pancan.org/news/fda-approves-rasonque-daraxonrasib/ to learn more about RASONQUE™, including what this FDA approval means, the survival benefit for people with pancreatic cancer, potential side effects, insurance coverage and how PanCAN Patient Services can help. 💜

08/26/2026

Doggedly determined to fight pancreatic cancer. 💜

08/25/2026

Each fall, the Kelly's Heroes running team follows in Steve's footsteps by taking on races like the OCNJ half-marathon, the Philadelphia Marathon and the Philadelphia Distance Run. If you're a runner who wants to make your miles more meaningful, pick any race and join our team! We make it easy to add a profile on our fund-raising page. Questions? Message our intrepid team captain Bill Kettelberger.

Join Us in the Fight Against Pancreatic CancerKelly’s Heroes is lacing up again, hitting the streets of Ocean City, N.J., and Philadelphia to raise funds and…

08/21/2026

⛳️The Kelly's Heroes Teed Off Golf Outing is just 4 weeks away - Sept. 17, 2026, at Mercer Oaks in Princeton Junction, N.J. There's no better way to remember Steve Kelly than to gather with friends, support cancer research and bring hope to pancreatic cancer patients. Our outing is a best-ball scramble with a 9 a.m. shotgun start. Play 18 holes on the impeccable Mercer Oaks course, take your best swing at a hole-in-one prize courtesy of Audi of Princeton, test yourself in our putting contest, enjoy a post-round buffet and cocktails, win incredible auction and raffle prizes and more!

Most importantly, as an all-volunteer 501c3 Kelly's Heroes makes sure that every penny raised helps patients access cutting-edge care to increase survival. Join us for a memorable day!

👉To register, go to www.kellysheroes.ngo/join-us.

Many thanks to our generous sponsors: Blue Rock Construction, Pennsylvania Steel Company, CMI Cabinets, M&T Bank, Habib Law, IBEW, Eaton Steel, Patriot Wealth Management, Leo Insurance, Fields Printwear and Underground Graphics.

08/17/2026

On , a salute to the donors, volunteers, sponsors & supporters who help us wage hope. You’re all heroes to us! 💜

08/17/2026

On , we're celebrating YOU! We couldn't wage hope without the energy and generosity of our donors, volunteers, sponsors and supporters. You're all heroes to us. 💜

08/11/2026

Huge thanks to Blue Rock Construction Inc., Title Sponsor for our Teed Off Golf Outing to Fight Pancreatic Cancer Sept. 17 at Mercer Oaks. Steve Kettelberger and the Blue Rock team have been with us since year 1 of our golf event - remembering Steve and waging hope! We couldn't do it without them! If you'd like to join us as an individual golfer, foursome or sponsor, go to www.kellysheroes.ngo/join-us for more information. See you on the links!

06/24/2026

For anyone interested in learning more about the latest exciting developments in pancreatic cancer research, check out this webinar tomorrow from our colleagues at Pancreatic Cancer Action Network. There's never been more hope for greater survival with this disease. Here's a chance to learn more and spread the word about new treatment options and clinical trials.

Join PanCAN for our virtual event, KRAS and Pancreatic Cancer: Entering a New Era of Treatment, where we'll discuss the current moment in KRAS research and what the newest discoveries may mean for patients now and in the future. 🧬

RSVP now at 🔗 pancan.org/KRAS2026.

06/07/2026

Today, on National Cancer Survivors Day, we celebrate the warriors. They inspire our work to ensure that more patients can live their lives - cancer be damned.

06/02/2026

It’s being hailed as a “transformative” advance in the treatment of pancreatic cancer. A new drug called daraxonrasib doubled the survival of patients with advanced pancreatic cancer compared to chemotherapy - without all the toxic side effects of chemo. This could be huge. The clinical trial results sparked a spontaneous standing ovation among cancer researchers when first presented this week at the American College of Clinical Oncology conference in Chicago.

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.